Formulary
Obinutuzumab [Specialist drug]: Indications, Dosing, Side Effects and Interactions
Obinutuzumab [Specialist drug] clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Obinutuzumab [Specialist drug]: Indications, Dosing, Side Effects and Interactions
Obinutuzumab [Specialist drug] clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Chronic lymphocytic leukaemia,Follicular lymphoma**
- **Adult** (By Intravenous Infusion): Specialist drug - access specialist resources for dosing information.
Contraindications
For obinutuzumab [Specialist drug] Contra-indications, further information For obinutuzumab contra-indications, consult product literature.
Side effects
For obinutuzumab [Specialist drug] Common or very common Alopecia; anaemia; arrhythmias; arthralgia; asthenia; chest pain; constipation; cough; depression; diarrhoea; dyspepsia; eye erythema; fever; gastrointestinal disorders; heart failure; hypertension; hyperuricaemia; increased risk of infection; infusion related reaction; leucopenia; lymph node pain; nasal complaints; neutropenia; night sweats; pain; skin reactions; squamous cell carcinoma; thrombocytopenia; tumour lysis syndrome; urinary disorders; weight increased Frequency not known Acute coronary syndrome; angina pectoris; chills; dizziness; dyspnoea; flushing; headache; hypersensitivity; hypotension; nausea; progressive multifocal leukoencephalopathy (PML); reactivation of infections; vomiting Side-effects, further information Cytokine release syndrome Fatalities following severe cytokine release syndrome (characterised by severe dyspnoea) and associated with features of tumour lysis syndrome have occurred after infusions of anti-lymphocyte monoclonal antibodies. Patients with a high tumour burden as well as those with pulmonary insufficiency or infiltration are at increased risk and should be monitored very closely (and a slower rate of infusion considered). Infusion-related side-effects In rare cases infusion reactions can be fatal. Infusion-related side-effects occur predominantly during the first infusion. Patients should receive premedication before administration of anti-lymphocyte monoclonal antibodies to reduce these effects. The infusion might need to be stopped temporarily and the infusion-related effects treated. Progressive Multifocal Leukoencephalopathy (PML) If suspected, treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, obinutuzumab should be permanently discontinued.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Obinutuzumab [Specialist drug] in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

